Abstract
In the study, it is aimed to research the likely role of visfatin in hyperthyroid and subclinical hyperthyroid status related to dislipidemia, after determining the visfatin and PON-1 levels thirty healthy individuals were enrolled in this study as control group and thirty hyperthyroidism patient’s with dyslipidemia they were treated with. The subjects aged ranged (30–50) years and with BMI (25–29) kg/m2. Serum was used in determination of lipid profile total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), thyroid threonine (T3) and thyroxin (T4), thyroid stimulating hormone (TSH), visfatin and paraoxonase-1 (PON-1). The results showed significant increase in T3, T4, TC, TG, LDL and VLDL in patient group when comparing to control group. While significant decrease was found in TSH and HDL in patient group when comparing to control group. The results also represented significant increase in visfatin levels in patient group comparing to control group. While there are significant reducation in PON-1 levels in patient group comparing to control group. The conclusion could be drown from this study that visfatin and PON-1 effected hyperthyroidism patient’s with dyslipidemia All the patients in hyperthyroid group were heterozygotes for Familial Hypercholesterolemia is a disorder that is passed down through families. It causes LDL (bad) cholesterol level to be very high. The condition begins at birth and can cause heart attacks at an early age.
Similar content being viewed by others
References
Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, et al. Harper’s illustrated biochemistry. 30th ed. New York: Mc Graw Hill Lange; 2017.
Shivanada NB. Manipal manual of clinical biochemistry. 3rd ed. New Delhi: Jaypee brothers medical publishers (P) Ltd; 2008.
Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes. 2010;17:408–13.
Reamy BV. Hyperlipidemia management for primary care: an evidence-based approach. 1st ed. New York: Springer; 2009.
Garten A, Petzold S, Barnikol-Oettler A, Korner A, Thasler WE, et al. Nicotinamide phosphoribosyl transferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun. 2010;391(1):376–81.
Costford SR, Bajpeyi S, Pasarica M, Albarado DC, Thomas SC, et al. Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab. 2010;98:E117–26.
Gligori R, Zdremtan D, Pilat L, Matei I, Ionescu-Tirgoviste C, Crisnic I. Correlations of visfatin with the lipidic metabolism in diabetic and obese patients. Proc Rom Acad Ser B. 2012;1:37–43.
Mancini A, Festa R, Raimondo S, Pontecorvi A, Littarru GP. Hormonal influence on Coenzyme (Q10) levels in blood plasma. Int J Mol Sci. 2011;12:9216–25.
Rajkovic MG, Rumora L, Barisic K. The paraoxonase 1, 2 and 3 in humans. Biochem Med. 2011;21:122–30.
Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol. 2005;11:7351–4.
Bhagwat K. Xanthine oxidase and paraoxonase-1 as new markers in the diagnosis and prognosis of organophosphorus pesticide poisoning. Int J Biol Res. 2013;1(2):10–4.
Shekhanawar M, Shekhanawar SM, Krisnaswamy D, Indumati V, Satishkumar D, et al. The role of ‘paraoxonase-1 activity’ as an antioxidant in coronary artery diseases. J Clin Diagn Res. 2013;7(7):1284–7.
Camuzcuoğlu H, Toy H, Vural M, Camuzcuoğlu A, Taşkın A, et al. Serum paraoxonase and arylesterase activities in iron deficiency anemia during pregnancy. Turk J Med Sci. 2011;41:185–91.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative. Clin Chem. 1972;81:499–502.
Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):408–13.
Mondal SI, Das SA, Akter A, Hasan R, Talukdar SA, et al. Thyroid hormone and its correlation with age, sex and serum lipid levels in hypothyroid and euthyroid sylheti populations in Bangladesh. J Clin Diagn Res. 2011;5(7):1347–51.
Gholamhoseinian A, Shahouzehi B, Sharifi-far F. Inhibitory activity of some plant methanol extracts on 3-hydroxyl-3-methylglutaryl coenzyme a reductase. Int J Pharmacol. 2010;6(5):705–11.
Oravec S, Gruber K, Dostal E, Mikl J. Hyper-betalipoproteinemia LDL 1,2: a newly identified nonatherogenic hypercholesterolemia in a group of hypercholesterolemic subjects. Neuro Endocrinol Lett. 2011;32:322–7.
Zheng C, Khoo C, Furtado J, Sacks FM. A polipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense LDL phenotype. Circulation. 2010;121(15):1722–34.
Abbas JMK, Chakraborty J, Akanji AO, Doi SAR. Hypothyroidism results in small dense LDL independent of IRS traits and hypertriglyceridemia. Endocr J. 2008;55:381–9.
Biondi B. How could we improve the increased cardiovascular mortality in patients with overt and subclinical hyperthyroidism? Eur J Endocrinol. 2012;167:295–9.
Saddi-Rosa P, Oliveira CSV, Giuffrida FMA, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Syndr. 2010;2:21.
Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009;71(2):202–7.
Lu LF, Yang SS, Wang CP, Hung WC, Yu TH, et al. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis. 2009;18(5):354–9.
Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta. 2009;410(1–2):1–12.
Sheu JJ, Kang JH, Lin HC, Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke. 2010;41:961–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shafeeq, N.K. Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient’s with Dyslipidemia. Ind J Clin Biochem 34, 101–107 (2019). https://doi.org/10.1007/s12291-017-0717-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-017-0717-7